PPMD For You: Schedule a one-to-one meeting for personalized support.powered by Calendly
June 10, 2025 /
Webinar: Dyne Therapeutics — The Clinical Impact of the FORCE™ Platform for Duchenne
by: Parent Project Muscular Dystrophy
Dyne Therapeutics joined PPMD on Wednesday, June 4, 2025 for a community webinar on the DELIVER clinical trial evaluating DYNE-251. The Dyne team provided the latest updates on the Phase 1/2 global DELIVER study of the company’s investigational therapy for individuals living with Duchenne who are amenable to exon 51 skipping.